Please provide your email address to receive an email when new articles are posted on . In this video, Alokkumar Jha, PhD, MSc, BE, spoke with Healio about key presentations from the American ...

Biohaven's (BHVN) first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel ...

Poster Presentation Title: Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing ...

WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (VIGL) (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the ...

The presentation, titled, "PrimeC, An Oral Candidate for Amyotrophic Lateral Sclerosis, Meets Primary and Secondary Endpoints in the Phase 2b PARADIGM Trial," was presented yesterday as an Emerging ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (”Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the ...

Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology – Data highlight long-term and real-world efficacy of SOLIRIS® (eculizumab) in patients ...

Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover advanced therapeutics, today announced that new results from a Phase 2 clinical trial of NB-001 ...

The FDA is scheduled to rule on BioXcel Therapeutics, Inc.'s new drug application for BXCL501. Akebia Therapeutics and Amylyx Pharmaceuticals came under selling pressure due to adverse regulatory ...